Navinta Faces New Suit Over Generic Naropin ANDA

Law360, New York (January 7, 2011, 3:41 PM EST) -- APP Pharmaceuticals LLC has taken a new shot at Navinta LLC for attempting to market a generic version of APP's injectable pain management drug Naropin, alleging that such a generic would infringe two APP-held patents.

APP filed a complaint in the U.S. District Court for the District of New Jersey on Thursday in defense of U.S. Patent Nos. 5,670,524 and 5,834,489, both titled “Methods and Compositions for the Treatment of Pain Utilizing Ropivacaine.”

Navinta's abbreviated new drug application for a generic of Naropin willfully infringes both...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.